Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced today that it has joined the Jupiter Life Science Initiative (JLSI) in Jupiter, Florida. Stuart will establish its research and development laboratory facility there, where the company will conduct a series of pre-clinical development efforts to advance its two platform technologies, PolyColTM (PolyCol), and TheraColTM(TheraCol).
The Jupiter Life Science Initiative’s goals are to enhance education and foster research in the life sciences while fostering research and collaboration with local biotechnology and life science companies. Leading research institutes, including the Max Planck Florida Institute for Neuroscience and The Scripps Research Institute, are co-located on Florida Atlantic University’s John D. MacArthur Campus. The proximity of the institutes encourages collaboration of faculty members, students and local life science companies.
PolyCol is a patented synthetic polypeptide that mimics human collagen. PolyCol targets and heals damaged collagen in the body, and can also deliver a chemically linked therapeutic, making it an ideal combination therapy for a variety of clinical conditions. Stuart is developing its first product, ST-100, as a drop formulation for dry eye syndrome, to heal damage to conjunctival surfaces caused by dry eye, providing rapid relief of signs and symptoms of the indication.
TheraCol is a patented resorbable device designed to deliver a therapeutic on a controlled basis over an extended time. The device can be programmed to resorb into the body between one and eight months. The technology is ideal for clinical indications where sustained and safe delivery of a therapeutic is indicated. Stuart is developing its second product, ST-101, as a small (2mm X 4mm) insert, an extraocular device as a treatment for glaucoma. Stuart will be testing various therapeutics in the TheraCol platform, and also certain PolyCol – TheraCol combinations.
“Stuart Therapeutics is proud to be associated with the Jupiter Life Sciences Institute,” said Eric Schlumpf, President and CEO of Stuart Therapeutics, Inc. “Gaining access to the Florida Atlantic University Honors Program, and Scripps Research and Max Planck Institutes’ programs is a significant benefit and accelerator for our development programs.”
About Stuart Therapeutics:
Stuart Therapeutics is a pre-clinical stage pharmaceutical company focused on the development of PolyCol, a collagen mimetic peptide therapeutic platform, and TheraCol, a flexible drug delivery platform. The company is developing ophthalmologic applications for these technologies.
ST-100 and ST-101 are candidate therapeutics that are in pre-clinical evaluation and that have not been approved by the U.S. Food and Drug Administration (FDA) for use in treating, preventing, curing or diagnosing any disease or disorder. Similarly, the statements contained in this Announcement have not been evaluated by the FDA, and may be considered “forward-looking statements” under applicable securities laws. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Although forward-looking statements contained in this presentation are based upon what management of Stuart Therapeutics believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Stuart Therapeutics undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
Stuart Therapeutics, Inc.
Email: [email protected]